Market capitalization | $220.00k |
Enterprise Value | $-2.28m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | 0.25 |
EV/Sales (TTM) EV/Sales | -6.91 |
P/S ratio (TTM) P/S ratio | 0.67 |
P/B ratio (TTM) P/B ratio | 0.06 |
Revenue growth (TTM) Revenue growth | -47.93% |
Revenue (TTM) Revenue | $330.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Motus GI Holdings, Inc.:
1 Analyst has issued a forecast Motus GI Holdings, Inc.:
Mar '24 |
+/-
%
|
||
Revenue | 0.33 0.33 |
48%
48%
|
|
Gross Profit | -0.59 -0.59 |
36%
36%
|
|
EBITDA | -8.72 -8.72 |
48%
48%
|
EBIT (Operating Income) EBIT | -9.31 -9.31 |
47%
47%
|
Net Profit | -11 -11 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.
Head office | United States |
CEO | Mark Pomeranz |
Employees | 15 |
Founded | 2008 |
Website | www.motusgi.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.